For individuals with symptomatic disorder requiring therapy, ibrutinib is usually proposed depending on 4 section III randomized clinical trials comparing ibrutinib with chlorambucil monotherapy106 and other frequently used CIT combinations, particularly FCR, bendamustine plus rituximab and chlorambucil in addition obinutuzumab (ClbO).107–109 Ibr